Evidence map›Paper›PMID 40331983›Full record

ReviewDeutsches Arzteblatt international2025

Inflammatory Skin Diseases: The Importance of Immunological Signatures.

Natalie Garzorz-Stark, Stephan Weidinger, Michael Sticherling, Kamran Ghoreschi, Alexander Enk, Kilian Eyerich

Abstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Problems associated with the ATC system of drug classification.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Natalie Garzorz-StarkKarolinska Institute, Stockholm; Clinic and Policlinic for Dermatology and Allergology, Technische Universität München; Clinic for Dermatology, Allergology and Venerology, University Hospital Schleswig-Holstein, Kiel; Clinic for Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen; Clinic for Dermatology, Allergology and Venerology, Charité-Universitätsmedizin Berlin; Department of Dermatology, Heidelberg University Hospital; Department of Dermatology and Venereology, University of Freiburg.
Stephan Weidinger
Michael Sticherling
Kamran Ghoreschi
Alexander Enk
Kilian Eyerich

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe understanding and classification of inflammatory skin diseases is shifting from a historical-descriptive perspective to a molecular-pathophysiological one based on immune response patterns. These are derived from a few key immunological mediators, each of which induces its own characteristic clinical, histopathological, and molecular patterns in the skin.

methodsThis discussion of the definition of the immune response patterns of inflammatory skin diseases is based on information from pertinent publications retrieved by a selective literature search. A systematic literature search was also conducted on the response of inflammatory skin diseases to treatment with specific biologic agents.

resultsThe described immune response patterns are: autoinflammation; type 1, cytotoxic; type 2a, eczematous; type 2b, blistering; type 3, psoriasiform; type 4a, fibrosing; and type 4b, granulomatous. Each signature can usually be treated in a targeted manner. In general, each therapeutic target structure is associated with an adequate treatment response if and only if the skin disease under treatment has the relevant signature type. Hardly any biomarkers are currently available for the determination of immune response patterns in routine clinical practice.

conclusionThe classification of inflammatory skin diseases by their immune response patterns opens up the prospect of specifically targeted immunotherapy for each immune response pattern regardless of the historical-descriptive disease entity. Targeting is intended to improve response rates. Initial findings suggest that this strategy is likely to succeed.

Indexed as

DermatitisSkin DiseasesBiomarkersHumansSkinBiomarkers

Identifiers

PMID40331983
PMCPMC12532202

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.